Phaseline

Targets › RARA

RARA (Retinoic acid receptor alpha): drug programs, companies and trials

14 programs from 13 companies in 34 trials: 23 Phase 2, 4 Phase 3, 4 Phase 4, 3 Phase 1; Oncology, Immunology, Infectious disease; next expected readout Dec 2026.

Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. (UniProt, P10276)

Open in Phaseline: the race on RARA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
IR INNOVATE RESEARCH PRIVATEAdapalene
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 4Acne; Viral WartsFeb 2027
Centre Hospitalier Universitaire de NiceIsotretinoin
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 3Acne VulgarisSep 2027
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityATRA (All-trans retinoic acid)
Retinoic acid receptor agonist
RARA, RARB, RARGPhase 2Oral Cavity CancerDec 2026
Nagoya Universitytamivarotene (AM80)
Retinoic acid receptor alpha (RARα) agonist
RARAPhase 2Urothelial Carcinoma BladderMar 2027
St. Petersburg State Pavlov Medical UniversityVitamin A
Retinoid receptor agonist; supports immune tolerance and graft-versus-host disease prevent
RARA, RARB, RARGPhase 2Acute Lymphoblastic LeukemiaMay 2027
Children's Hospital Medical Center, CincinnatiVitamin A
Retinoid receptor ligand; immunomodulatory effects on T cell differentiation and GVHD
RXRA, RXRB, RXRG, RARA, RARBPhase 2Graft Vs Host DiseaseAug 2027
Children's Oncology GroupIsotretinoin
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 2Ganglioneuroblastoma, NodularSep 2027
Instituto do Cancer do Estado de São PauloATRA (All-trans retinoic acid)
Retinoic acid receptor agonist; induces differentiation of APL cells and degradation of PM
RARAPhase 2Acute Promyelocytic Leukemia (APL)Nov 2028
Instituto do Cancer do Estado de São PauloRealgar-Indigo Naturalis Formulation (Oral Arsenic)
Arsenic trioxide induces differentiation and apoptosis of acute promyelocytic leukemia cel
PML, RARAPhase 2Acute Promyelocytic Leukemia (APL)Nov 2028
HighField BiopharmaceuticalsTretinoin
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 2Glioma; Acne Vulgaris; Melasma (Facial Melasma); APL …Dec 2028
Fudan UniversityAll Trans Retinoic Acid (ATRA)
Retinoic acid receptor agonist
RARA, RARB, RARGPhase 2Triple Negative Breast Cancer (TNBC)Sep 2029
Rege NephroTamibarotene
Retinoic acid receptor beta agonist; Retinoic acid receptor alpha agonist
RARB, RARAPhase 2Autosomal Dominant Polycystic Kidney Disease (ADPKD); HFpEF - Heart Failure With Preserved Ejection Fraction–
Zagazig UniversityIsotretinoin
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 1OnychomycosisDec 2026
National Cancer Institute (NCI)Isotretinoin
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 1Recurrent NeuroblastomaMar 2027

Conditions

Acute Promyelocytic Leukemia (APL) (2) Acne Vulgaris (2) Glioma (2) Persistent Isolated Chemotherapy-Induced Thrombocytopenia (2) Recurrent Neuroblastoma (1) Onychomycosis (1) Urothelial Carcinoma Bladder (1) Acne (1) Viral Warts (1) Melasma (Facial Melasma) (1) APL (1) Oropharynx Cancer (1)

Modalities

small molecule (9), antibody (3), mixed (2)

Companies

Instituto do Cancer do Estado de São Paulo (2) National Cancer Institute (NCI) (1) Zagazig University (1) Centre Hospitalier Universitaire de Nice (1) Nagoya University (1) IR INNOVATE RESEARCH PRIVATE (1) HighField Biopharmaceuticals (1) Children's Oncology Group (1) Children's Hospital Medical Center, Cincinnati (1) Fudan University (1) St. Petersburg State Pavlov Medical University (1) Rege Nephro (1) Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1)

Related targets

RARB (11) RARG (9) PML (1) RXRA (1) RXRB (1) RXRG (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.